Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2022

Open Access 01-12-2022 | Kidney Cancer | Research

Epstein–Barr virus infection is associated with the nuclear factor-kappa B p65 signaling pathway in renal cell carcinoma

Authors: Ali Farhadi, Sepide Namdari, Pei Pei Chong, Bita Geramizadeh, Abbas Behzad-Behbahani, Zamberi Sekawi, Sedigheh Sharifzadeh

Published in: BMC Urology | Issue 1/2022

Login to get access

Abstract

Background

There have been few studies regarding viral involvement in the pathogenesis of renal cell carcinoma (RCC). The aim of this study was to examine the possible association of Epstein–Barr virus (EBV) infection with clinicopathological features and cellular biomarkers including p53, p16INK4a, Ki-67 and nuclear factor-kappa B (NF-κB) in RCC tumors.

Methods

In this prospective study, 122 histologically confirmed Formalin-fixed Paraffin-embedded RCC tissue specimens along with 96 specimens of their corresponding peritumoral tissues and 23 samples of blunt renal injuries were subjected to nested polymerase chain reaction (nPCR) in order to amplify EBV DNA sequences. The expression of p53, p16INK4a, Ki-67 and NF-κB was investigated by immunohistochemistry (IHC) assay. Statistical analysis was employed to demonstrate the possible associations.

Results

Infection with EBV was found to be significantly associated with RCC. Our results indicate that p65 NF-κB signaling pathway is probably involved in EBV-mediated RCC pathogenesis. Moreover, we found p53, Ki-67 and cytoplasmic NF-κB expression to be associated with tumor nuclear grade in RCC patients. The expression of p53 and Ki-67 was associated with primary tumor category as well. In addition, p53 overexpression was significantly more frequent among nonconventional RCC tumors than the conventional histologic type.

Conclusions

Infection with EBV is likely to play an important role in the development of RCC through the constitutive and permanent activation of NF-κB p65 signaling pathway. However, more experiments and supporting data are required to reach a decisive conclusion.
Literature
1.
2.
3.
Koul H, Huh JS, Rove KO, et al. Molecular aspects of renal cell carcinoma: a review. Am J Cancer Res. 2011;1(2):240.PubMed
4.
5.
6.
Liao JB. Cancer issue: viruses and human cancer. Yale J Biol Med. 2006;79(3–4):115.PubMed
7.
Hutt-Fletcher L. Cancers in people with HIV and AIDS: Epstein–Barr virus. 1st ed. New York: Springer; 2014. p. 75–85.
8.
Ponticelli C. Herpes viruses and tumours in kidney transplant recipients. The role of immunosuppression. Nephrol Dial Transplant. 2011;26(6):1769–75.PubMedCrossRef
9.
Iwama H, Horikoshi S, Shirato I, et al. Epstein–Barr virus detection in kidney biopsy specimens correlates with glomerular mesangial injury. Am J Kidney Dis. 1998;32(5):785–93.PubMedCrossRef
10.
Becker JL, Miller F, Nuovo GJ, et al. Epstein–Barr virus infection of renal proximal tubule cells: possible role in chronic interstitial nephritis. J Clin Invest. 1999;104(12):1673–81.PubMedPubMedCentralCrossRef
11.
Törnell J, Farzad S, Espander-Jansson A, et al. Expression of Epstein–Barr nuclear antigen 2 in kidney tubule cells induce tumors in transgenic mice. Oncogene. 1996;12(7):1521–8.PubMed
12.
Shimakage M, Kawahara K, Harada S, et al. Expression of Epstein–Barr virus in renal cell carcinoma. Oncol Rep. 2007;18(1):41–6.PubMed
13.
Karaarslan S, Şen N. Investigation of the relationship of Epstein–Barr virus with in situ hybridization in renal-cell carcinomas. Ann Diagn Pathol. 2018;34:45–9.PubMedCrossRef
14.
Kryst P, Poletajew S, Wyczałkowska-Tomasik A, et al. Epstein–Barr virus and human adenovirus viremia in renal tumors is associated with histological features of malignancy. J Clin Med. 2020;9(10):3195.PubMedCentralCrossRef
15.
Hollstein M, Rice K, Greenblatt M, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 1994;22(17):3551.PubMedPubMedCentral
16.
Wang Z, Peng S, Jiang N, et al. Prognostic and clinicopathological value of p53 expression in renal cell carcinoma: a meta-analysis. Oncotarget. 2017;8(60):102361.PubMedPubMedCentralCrossRef
17.
Kim HL, Seligson D, Liu X, et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res. 2004;10(16):5464–71.PubMedCrossRef
18.
Zubac DP, Bostad L, Kihl B, et al. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival. J Urol. 2009;182(5):2144–9.PubMedCrossRef
19.
Kankaya D, Kiremitci S, Tulunay O, et al. NF-κB, and p53 expression in clear cell renal cell carcinoma: impact on outcome. Pathol Res Pract. 2015;211(7):505–12.PubMedCrossRef
20.
Lok SS, Stewart JP, Kelly BG, et al. Epstein–Barr virus and wild p53 in idiopathic pulmonary fibrosis. Respir Med. 2001;95(10):787–91.PubMedCrossRef
21.
Yi F, Saha A, Murakami M, et al. Epstein–Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities. Virology. 2009;388(2):236–47.PubMedCrossRef
22.
Shao JY, Ernberg I, Biberfeld P, et al. Epstein–Barr virus LMP1 status in relation to apoptosis, p53 expression and leucocyte infiltration in nasopharyngeal carcinoma. Anticancer Res. 2004;24(4):2309–18.PubMed
23.
24.
Liggett WH Jr, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol. 1998;16(3):1197–206.PubMedCrossRef
25.
26.
Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264(5157):436–40.PubMedCrossRef
27.
Skalska L, White RE, Franz M, et al. Epigenetic repression of p16INK4A by latent Epstein–Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathog. 2010;6(6):e1000951.PubMedPubMedCentralCrossRef
28.
McGuire BB, Fitzpatrick JM. Biomarkers in renal cell carcinoma. Curr Opin Urol. 2009;19(5):441–6.PubMedCrossRef
29.
Visapää H, Bui M, Huang Y, et al. Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology. 2003;61(4):845–50.PubMedCrossRef
30.
Xie Y, Chen L, Ma X, et al. Prognostic and clinicopathological role of high Ki-67 expression in patients with renal cell carcinoma: a systematic review and meta-analysis. Sci Rep. 2017;7(1):1–9.
31.
Zheng X, Hu L, Chen F, et al. Expression of Ki67 antigen, epidermal growth factor receptor and Epstein–Barr virus-encoded latent membrane protein (LMP1) in nasopharyngeal carcinoma. Eur J Cancer B Oral Oncol. 1994;30b(5):290–5.PubMedCrossRef
32.
Gilmore TD. The Rel/NF-κB signal transduction pathway: introduction. Oncogene. 1999;18(49):6842–4.PubMedCrossRef
33.
Dolcet X, Llobet D, Pallares J, et al. NF-kB in development and progression of human cancer. Virchows Arch. 2005;446(5):475–82.PubMedCrossRef
34.
Matušan-Ilijaš K, Damante G, Fabbro D, et al. Osteopontin expression correlates with nuclear factor-κB activation and apoptosis downregulation in clear cell renal cell carcinoma. Pathol Res Pract. 2011;207(2):104–10.PubMedCrossRef
35.
Ng KL, Yap NY, Rajandram R, et al. Nuclear factor-kappa B subunits and their prognostic cancer-specific survival value in renal cell carcinoma patients. Pathology. 2018;50(5):511–8.PubMedCrossRef
36.
Yin H, Qu J, Peng Q, et al. Molecular mechanisms of EBV-driven cell cycle progression and oncogenesis. Med Microbiol Immunol. 2019;208(5):573–83.PubMedCrossRef
37.
Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183(2):131–3.PubMedCrossRef
38.
Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6(7):655–64.PubMedCrossRef
39.
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.PubMedCrossRef
40.
Guinan P, Sobin LH, Algaba F, et al. TNM staging of renal cell carcinoma: workgroup no. 3. Cancer. 1997;80(5):992–3.PubMedCrossRef
41.
Saiki RK, Gelfand DH, Stoffel S, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 1988;239(4839):487–91.PubMedCrossRef
42.
Espy MJ, Mitchell PS, Persing DH, et al. Diagnostic virology protocols: herpesviruses. 2nd ed. Totowa: Springer; 1998. p. 89–101.CrossRef
43.
Zigeuner R, Ratschek M, Rehak P, et al. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Urology. 2004;63(4):651–5.PubMedCrossRef
44.
Kankuri M, Söderström KO, Pelliniemi TT, et al. The association of immunoreactive p53 and Ki-67 with T-stage, grade, occurrence of metastases and survival in renal cell carcinoma. Anticancer Res. 2006;26(5B):3825–33.PubMed
45.
Olumi AF, Weidner N, Presti JC Jr. p53 immunoreactivity correlates with Ki-67 and bcl-2 expression in renal cell carcinoma. Urol Oncol. 2001;6(2):63–7.
46.
Gabrielli Fregonesi PA, Teresa DB, Duarte RA, et al. p16INK4A immunohistochemical overexpression in premalignant and malignant oral lesions infected with human papillomavirus. J Histochem Cytochem. 2003;51(10):1291–7.CrossRef
47.
Farhadi A, Behzad-Behbahani A, Geramizadeh B, et al. High-risk human papillomavirus infection in different histological subtypes of renal cell carcinoma. J Med Virol. 2014;86(7):1134–44.PubMedCrossRef
48.
Zhou S, Ye W, Shao Q, et al. Prognostic significance of XIAP and NF-κB expression in esophageal carcinoma with postoperative radiotherapy. World J Surg Oncol. 2013;11(1):1–7.CrossRef
49.
50.
Kim KH, Han EM, Lee ES, et al. Epstein–Barr virus infection in sarcomatoid renal cell carcinoma tissues. BJU Int. 2005;96(4):547–52.PubMedCrossRef
51.
52.
Hainaut P, Soussi T, Shomer B, et al. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res. 1997;25(1):151–7.PubMedPubMedCentralCrossRef
53.
Noon AP, Vlatković N, Polański R, et al. p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets? Cancer. 2010;116(4):780–90.PubMedCrossRef
54.
Hodges A, Talley L, Gokden N. Human Papillomavirus DNA and P16INK4A are not detected in renal tumors with immunohistochemistry and signal-amplified in situ hybridization in paraffin-embedded tissue. Appl Immunohistochem Mol Morphol. 2006;14(4):432–5.PubMedCrossRef
55.
Ikuerowo SO, Kuczyk MA, von Wasielewski R, et al. p16INK4a expression and clinicopathologic parameters in renal cell carcinoma. Eur Urol. 2007;51(3):732–8.PubMedCrossRef
56.
Yildiz E, Gokce G, Kilicarslan H, et al. Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma. BJU Int. 2004;93(7):1087–93.PubMedCrossRef
57.
Bui MH, Visapaa H, Seligson D, et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol. 2004;171(6 Part 1):2461–6.PubMedCrossRef
58.
Phuoc NB, Ehara H, Gotoh T, et al. Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma. Urology. 2007;69(5):843–8.PubMedCrossRef
59.
Rioux-Leclercq N, Turlin B, Bansard JY, et al. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology. 2000;55(4):501–5.PubMedCrossRef
60.
Luo Y, Liu Y, Wang C, et al. Signaling pathways of EBV-induced oncogenesis. Cancer Cell Int. 2021;21(1):1–11.CrossRef
61.
Pakdel F, Farhadi A, Pakdel T, et al. The frequency of high-risk human papillomavirus types, HPV16 lineages, and their relationship with p16 INK4a and NF-κB expression in head and neck squamous cell carcinomas in Southwestern Iran. Braz J Microbiol. 2021;52(1):195–206.PubMedCrossRef
62.
63.
Chen C, Edelstein LC, Gélinas C. The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-xL. Mol Cell Biol. 2000;20(8):2687–95.PubMedPubMedCentralCrossRef
64.
Meteoglu I, Erdogdu IH, Meydan N, et al. NF-KappaB expression correlates with apoptosis and angiogenesis in clear cell renal cell carcinoma tissues. J Exp Clin Cancer Res. 2008;27(1):1–9.CrossRef
Metadata
Title
Epstein–Barr virus infection is associated with the nuclear factor-kappa B p65 signaling pathway in renal cell carcinoma
Authors
Ali Farhadi
Sepide Namdari
Pei Pei Chong
Bita Geramizadeh
Abbas Behzad-Behbahani
Zamberi Sekawi
Sedigheh Sharifzadeh
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2022
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-022-00964-2

Other articles of this Issue 1/2022

BMC Urology 1/2022 Go to the issue

Research

Prognostic significance of immunoscore related markers in bladder cancer

Case report

Granulation tissue-type hemangioma of ureter: a highly misdiagnosed disease (a rare case report and literature review)

Research

Safe provision of systemic anti-cancer treatment for urological cancer patients during COVID-19: a tertiary centre experience in the first wave of COVID-19

Research

A warning system for urolithiasis via retrograde intrarenal surgery using machine learning: an experimental study

Research

High stone-free rate immediately after suctioning flexible ureteroscopy with Intelligent pressure-control in treating upper urinary tract calculi

Research

Relationship between sperm NAD + concentration and reproductive aging in normozoospermia men:A Cohort study